Dong-A Mulls Fresh Options After Allergan Ends Evogliptin Deal
Executive Summary
With Allergan handing back the global development and sales rights of evogliptin as a NASH therapy to Dong-A, the South Korean firm is now considering an alternative business model around the DPP-4 inhibitor.
You may also be interested in...
Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals
Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.
Tobira, Dong-A Stick To NASH Plans Despite CENTAUR Results
The failure of Tobira's cenicriviroc to meet its primary endpoint in the CENTAUR study has raised some concerns in South Korea over the prospects for a combo therapy with Dong-A ST's evogliptin. But the two firms are sticking to their clinical development plans based on the positive secondary endpoint outcome in the study.
Korea Regulatory Streamlining Plans Eye Innovation, Commercialization Support
South Korea's drug ministry, together with consumer and business groups, announces a raft of major regulatory innovation tasks it aims to achieve over the next few years, a major goal being to speed up patient access to innovation.